Comparative analysis of specific and non-specific markers in patients with different stages of liver fibrosis in chronic hepatitis C

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To study a possible relationship between individual stages of liver fibrosis (LF) in patients with chronic hepatitis C (CHC) and their virological, serological, and immunogenetic parameters. Subjects and methods. Five groups of150 patients were formed by the stage of LF. The latter was determined employing transient fibroelastometry. Hepatitis C virus (HCV) RNA was detected and quantified by reverse transcription PCR using 2 versions of the RealBest HCV RNA kit. Antibodies to HCV were detected in the RecombiBest anti-HCV IgM and RecombiBest anti-HCV spectrum test systems. Polymorphic loci of the IFNL3 (rs8099917 T/G) and IFNL4 (rs1297960 C/T) genes were genotyped using the IL28B Immunogenetics kit. Results. Comparison of the virological parameters did not reveal a significant relationship to a certain stage of LF. Among specific antibodies, only anti-HCV IgM showed an association with the fibrosis stages F2-F4 (p < 0.001). The detection rate for these antibodies significantly increased from F0 (46.7%) to F4 (93.3%). The ratio of genotype variants for polymorphic loci of the IFNL3 and IFNL4 genes changed with increasing LF stages. In the liver cirrhosis group, the CT-TG genotype was dominant, the differences in participants with F0 were significant (p = 0.0009). Conclusion. The prognostic markers of impending liver cirrhosis include anti-HCV IgM in high titers and the CT-TG genotype in the polymorphic loci of the IFNL4 (rs1297960 C/T) and IFNL3 (rs8099917 T/G) genes.

Full Text

Restricted Access

About the authors

Lyudmila I. Nikolaeva

Honorary Academician N.F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of Russia

Email: l.i.nikolaeva@mail.ru
BD, leading researcher of laboratory of gene engineering products

Nadezhda G. Shevchenko

Honorary Academician N.F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of Russia; Russian Medical Academy of Continuing Professional Education, Ministry of Health

Email: dr.nadya@inbox.ru
junior researcher of laboratory of gene engineering products

Anna V. Dedova

Honorary Academician N.F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of Russia

Email: dedova.anna2010@mail.ru
research assistant of laboratory of gene engineering products

Georgiy V. Sapronov

Honorary Academician N.F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of Russia; Russian Medical Academy of Continuing Professional Education, Ministry of Health

Email: g_sapronov@mail.ru
PhD in medicine, senior researcher of laboratory of gene engineering products

Evgeniy I. Samokhvalov

Honorary Academician N.F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of Russia

Email: e-samokh@hotmail.com
PhD in biology, leading researcher of laboratory ofviral ecology

Artemiy A. Vakhromeev

Honorary Academician N.F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of Russia

Email: bioartemiyvakhrameev@gmail.com
junior researcher of laboratory of gene engineering products

References

  1. Daw M.A., El-Bouzedi A.A., Ahmed M.O., Dau A.A., Agnan M.M., Drah A.M. Geographic integration of hepatitis C. virus: A global threat. World J. Virol. 2016; 5(4): 170-82. https://doi.org/10.5501/wjv.v5.i4.170
  2. Petruzziello A., Marigliano S., Loquercio G., Cozzolono A., Cacciapuoti C. Global epidemiology of hepatitis C. virus infection: An up-date of the distribution and circulation of hepatitis C. virus genotypes. World J. Gastroenterol. 2016; 22(34): 7824-40. https://doi.org/10.3748/wjg.v22.i34.7824
  3. Чуланов В.П., Пименов Н.Н., Мамонов Н.А., Сагалова О.И., Шестакова И.В., Покровский В.И. Хронический гепатит С. как проблема здравоохранения России сегодня и завтра. Терапевтический архив 2015; (11): 5-10.
  4. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2014 году: Государственный доклад. М., 2015. http://rospotrebnadzor.ru/upload/iblock/22c/gd_2014_seb_dlya-sayta.pdf.
  5. Инфекционная заболеваемость в Российской Федерации за январь-декабрь 2021 г. http://www.rospotrebnadzor.ru
  6. Falada-Nwulia O., Suares-Cuervo C., Nelson D.R., Fried M.W., Segal J.B., Sulkowski M.S. Oral direct-acting agent therapy for hepatitis C. virus infection: a systematic review. Ann Intern Med. 2017; 166: 637-48. https://doi.org/10.7326/M16-2575
  7. Rosecrans A.M., Cheedalla A., Rives S.T., Scotti L.A., Harris R.E., Greenbaum A.H. et al. Public health clinic-based hepatitis C. treatment. Am. J. Prev. Med. 2020; 59: 420-7. https://doi.org/10.1016/j.amepre.2020.03.006
  8. World Health Organization. Global hepatitis report. Geneva, Swizerland: WHO, 2017. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/
  9. Bartenschlager R., Baumert T.F., Bukh J., Lemon M., Lindenbach S., Lohmann B. et al. Critical сhallenges and emerging opportunities in hepatitis C research in an era of potent antiviral therapy: considerations for scientists and funding agencies. Virus Res. 2018; 248: 53-62. https://doi.org/10.1016/j.virusres.2018.02.016
  10. Roche B., Coilly A., Duclos-Vallec J.C., Sammuel D. The impact of treatment of hepatitis C. with DA As on occurrence of HCC. Liver Int. 2018; 38(Suppl.1): 139-45. https://doi.org/10.1111/liv.13659
  11. Guarino M., Sessa A., Cossiga V., Special interest group on «Hepatocellular carcinoma and new anti-HCV therapies» of the Italian Association for the Study of the Liver. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: a few lights and many shadows. World J. Gastroenterol. 2018; 24: 2582-95. https://doi.org/10.3748/wjg.v24.2582
  12. Patel K., Friedrich-Rust M., Lurie Y., Grigorescu M., Stanclu C., Lee C.M. et al. FibroSURE and FibroScan in treatment response in chronic hepatitis C. virus. World J. Gastroenterol. 2011; 17(41): 4581-9. https://doi.org/10.3748/wjg.v17.i41.4581
  13. Bedossa P., Carrat F. Liver biopsy: the best, not the gold standard. J. Hepatol. 2009; 50(1): 1-3. https://doi.org/10.1016/jhep.2008.10.014
  14. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O’Huigin C. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C. virus. Nature 2009; 461(7265): 798- 801. https://doi.org/10.1038/nature08463
  15. Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J., Mueller T. et al. Genetic variation in IL28B is associated with chronic hepatitis C. and treatment failure: A Genome-Wide Association Study. Gastroenterology 2010; 38(4): 1338-45. https://doi.org/10.1053/j.gastro.2009.12/056
  16. Muir A.J. IL28B in the era of direct-acting antivirals for hepatitis C. J. Clin. Gastroenterol. 2013; 47(3): 222-7. https://doi.org/10.1097/MCG.0b013e3182680221
  17. Eslam M., Hashem A.M., Leung R., Romero-Gomez M., Berg T., Dore G.J. et al. Interferon-lambda rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat. Commun. 2015; (6): 6422. doi: 10.1038/ncomms7422
  18. Al-Qahtani A., Al-Anazi M., Abdo A.A., Sanai F.M., Al-Hamoudi W., Alswat K.A. et al. Correlation between genetic variations and serum level of interleukin 28B with genotypes and disease progression in chronic hepatitis C. virus infection. J. Immunol. Res. 2015; (1): 768470. https://doi.org/10.1155/2015/768470
  19. Ohno T., Mizokami M., Wu N., Saleh M.G., Ohba K.-I., Orito E. et al. New hepatitis C. virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 3a, 3b,4, 5a, and 6a. J. Clin. Microbiol. 1997; 35(1): 201-7. https://doi.org/10.1128/jcm.35.1.201-207
  20. Sanger F., Niclein S., Coulson A.R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA. 1977; 74: 5463-7. https://doi.org/10.1073/pnas.74.12.5463
  21. Nikolaeva L.I., Blokhina N.P., Tsurikova N.N., Voronkova N.V., Miminoshvili M.I., Braginsky D.M. et al. Virus-specific antibody titres in different phases of hepatitis C. virus infection. J. Viral. Hepatol. 2002; (9): 429-37. https://doi.org/10.1046/j.1365-2893.2002.00369.x
  22. Bortolotii F., Verucchi G., Camma C., Cabibbo G., Zancan L., Indolfi G. et al. Long-term course of chronic hepatitis C. in children: from viral clearance to end-stage liver disease. Gastroenterology 2008; 134(7): 1900-7. https://doi.org/10.1053/j.gastro.2008.02.082
  23. Roffi L., Redaelli A., Colloredo G., Minola E., Donada C., Picciotto A. Outcome of liver disease in a large cohort of histologically proven chronic hepatitis c: influence of HCV genotype. Eur. J. Gastroenterol. Hepatol. 2001; 13(5): 501-6.
  24. Bochud P.-Y., Cat T., Overbeck K., Bochud M., Dufour J.F., Mullhaupt B. et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J. Hepatol. 2009; 51(4): 655-66. https://doi.org/10.1016/j.hep.2009.05.016
  25. Wu N., Rao H.-Y., Yang W.-B., Gao Z.-L., Yang R.-F., Fei R. et al. Impact of hepatitis C. virus genotype 3 on liver diease progression in a Chinese national cohort. Chin. Med. J. (Engl.). 2020; 133(3): 253-61. https://doi.org/10.1097/CM9.0000000000000629
  26. Самохвалов Е.И., Николаева Л.И., Альховский С.В., Хлопова И.Н., Макашова В.В., Петрова Е.В. и др. Частота встречаемости отдельных субтипов вируса гепатита С. в Московском регионе. Вопр. вирусол. 2013; 58(1): 36-40.
  27. Mukomolov S., Trifonova G., Levakova I., Bolsun D., Krivanogova E. Hepatitis C. in the Russian Federation: challenges and future directions. Hepat. Med. 2016; (8): 51-60. https://doi.org/10.2147/HMER.S50172
  28. Жданов К.В., Гусев Д.А., Козлов К.В., Сукачев В.С., Шекуров А.В., Жабров С.С. и др. Взаимосвязь полиморфизмов гена ИЛ-28В, клинико-лабораторных и вирусологических показателей при хронической HCV-инфекции. Журн. инфектол. 2014; 6(4): 19-26.
  29. Tamaki N., Kurosaki M., Higuchi M., Takada H., Nakakuki N., Yasui Y. et al. Genetic polymorphisms of IL28B and PNPLA3 are predictive for HCV related rapid fibrosis progression and identify patients who require urgent antiviral treatment with new regimens. PLOS Оne 2015; 10(9): e0137351. https://doi.org/10.1371/journal.pone.0137351
  30. Zai M., Long J., Liu S., Liu C., Li L., Yang L., Li Y., Shu B. The burden of liver cirrhosis and underlying etiologies: results from the global burden of disease study 2017. Aging (Albany NY) 2021; 13(1): 279-300. https://doi.org/10.18632/aging.104127

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies